Isofol Medical AB (publ), founded in 2008, is a biotech company that is developing a new drug candidate for the treatment of advanced colorectal cancer.
Colorectal cancer (CRC) is the third most common form of cancer worldwide and there is a very high need for more effective drugs to treat this disease.
“Isofol will help extend life and improve the quality of life for cancer patients”
Arfolitixorin is being developed and commercialized through a global licensing agreement with Merck & Cie in Germany. The licensing agreement also grants Isofol access to the unique patented manufacturing process for arfolitixorin.
Isofol’s operations are based in Gothenburg, Sweden and the company’s shares are traded on Nasdaq Stockholm´s main market in the Mid Cap segment.
Last updated 11-07-2022